Obesity – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly prevalent disorders in China, the treatment options for obesity are limited. Wegovy, the only once-a-week injection with good weight-loss efficacy, was added to the obesity arsenal in 2024, providing a new solution for long-term weight management. This market is likely to witness strong growth over the 2024-2034 forecast period, fueled by the launch and uptake of several GLP-1 receptor agonists, including tirzepatide (Eli Lilly’s Zepbound), Innovent’s mazdutide, and a fixed-dose combination of cagrilintide + semaglutide (Novo Nordisk’s CagriSema). In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will influence the launch and uptake of new therapies in this highly lucrative market.
Questions answered
- What is the diagnosed prevalence of obesity in China, and how are obese patients treated today? Do treatment management strategies differ between urban and rural China?
- What are the key unmet needs in the management of obesity?
- How will the obesity therapy market evolve over the next 10 years?
- Who will be the leading players in the obesity / overweight therapy market in 2034?
Primary research: Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists in China
Epidemiology: Diagnosed prevalence of obesity and drug-eligible overweight patients in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key obesity therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)
Product description
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
